Related Experiment Videos
Comparative studies on nicotinic acid derivatives as hypolipoproteinemic agents
1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Karachi, Karachi-75270, Pakistan.
Pakistan Journal of Pharmaceutical Sciences
|January 18, 2006
Summary
New nicotinic acid derivatives, T1 and T2, show promise in lowering blood lipids by reducing very low-density lipoprotein (VLDL) production. These compounds may offer a safer alternative to existing lipid-lowering drugs.
Area of Science:
- Pharmacology
- Medicinal Chemistry
- Biochemistry
Background:
- Nicotinic acid is a lipid-lowering agent, but clinical use is limited by side effects.
- New nicotinic acid derivatives are synthesized to mitigate adverse effects.
- Antilipoproteinemic effects of novel compounds are investigated.
Purpose of the Study:
- To evaluate the hypolipoproteinemic effects of two novel nicotinic acid derivatives: 3-methoxy phenacyl nicotinium bromide (T1) and 2-methoxy phenacyl nicotinium bromide (T2).
- To compare the efficacy of T1 and T2 with standard drugs like aspirin and clofibrate.
Main Methods:
- Synthesis of two new nicotinic acid derivatives, T1 and T2.
- Administration of compounds at 30 mg/day to white male rabbits.
- Comparison of lipid profiles with aspirin and clofibrate as reference standards.
Main Results:
- Both T1 and T2 demonstrated significant hypolipoproteinemic effects in rabbits.
- The compounds likely reduce plasma lipoproteins by inhibiting hepatic very low-density lipoprotein (VLDL) production.
- This mechanism ultimately leads to a reduction in low-density lipoprotein (LDL) levels.
Conclusions:
- The synthesized nicotinic acid derivatives (T1 and T2) possess notable lipid-lowering properties.
- These compounds represent potential therapeutic agents for managing dyslipidemia.
- Further research is warranted to explore their clinical efficacy and safety profile.